Mangoceuticals, Inc. (MGRX) stock
MGRXNasdaqServices-Misc Health & Allied Services, NECFiscal year ends December 31
$0.15−0.03 (-16.22%)
Close on Nov 13, 2026Market cap $3.34MP/E –Yield –
Mangoceuticals ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Mangoceuticals's ebitda for the twelve months ending Sep 30, 2025 was -$19.06M. For fiscal 2024 it was -$7.96M.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | -$7.96M | – |
| FY2023 | Dec 31, 2023 | -$9.19M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2025 | Sep 30, 2025 | -$7.54M | – |
| Q2 FY2025 | Jun 30, 2025 | -$5.27M | – |
| Q1 FY2025 | Mar 31, 2025 | -$4.58M | – |
| Q4 FY2024 | Dec 31, 2024 | -$1.68M | – |
| Q3 FY2024 | Sep 30, 2024 | -$1.75M | – |
| Q2 FY2024 | Jun 30, 2024 | -$2.17M | – |
| Q1 FY2024 | Mar 31, 2024 | -$2.36M | – |
| Q4 FY2023 | Dec 31, 2023 | -$2.56M | – |
| Q3 FY2023 | Sep 30, 2023 | -$1.79M | – |
See a number that looks wrong?